Insulet (NASDAQ:PODD) Stock Gets Downgrade from Stifel Nicolaus

Insulet (NASDAQ:PODD – Get Free Report) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, MarketBeat reports. They presently have a $165.00 target price on the medical instruments supplier’s stock, down from their previous target price of $180.00. Stifel Nicolaus‘s price target would indicate a potential upside of 20.24% from the stock’s current price.

PODD has been the subject of several other research reports. Canaccord Genuity Group decreased their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. UBS Group lifted their price target on shares of Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a research note on Monday, September 21st. Robert W. Baird set a $175.00 price objective on Insulet in a research note on Thursday, August 6th. Finally, BTIG Research lowered Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $185.04.

Read Our Latest Research Report on PODD

Insulet Price Performance

PODD opened at $137.23 on Wednesday. The firm has a market cap of $9.52 billion, a P/E ratio of 22.35, a PEG ratio of 1.07 and a beta of 1.06. The firm has a 50-day moving average of $142.25 and a 200 day moving average of $171.25. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.24 earnings per share. On average, research analysts expect that Insulet will post 6.76 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Elevation Wealth Partners LLC lifted its holdings in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 104 shares in the last quarter. Stance Capital LLC boosted its position in shares of Insulet by 100.0% in the third quarter. Stance Capital LLC now owns 200 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 100 shares during the period. Activest Wealth Management boosted its position in shares of Insulet by 186.3% in the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 149 shares during the period. WPG Advisers LLC boosted its position in shares of Insulet by 169.3% in the third quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 171 shares during the period. Finally, State of Wyoming grew its stake in Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after acquiring an additional 73 shares in the last quarter.

Insulet Company Profile

(Get Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Further Reading

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.